

## PUBLIKATIONSLISTE

### Originalpublikationen

1. Gärtner R, Schopohl D, **Schäfer S**, Dugrillon A, Erdmann A, Toda S, Bechtner G. Regulation of Transforming Growth Factor- $\beta$ 1 messenger Ribonucleic Acid Expression in Porcine Thyroid Follicles *in vitro* by Growth Factors, Iodine, or  $\delta$ -Iodolactone.; *Thyroid* 1997; 7: 633-40
2. **Schäfer S**, Kajimura M, Tsuyama S, Uchida K, Sato E, Inoue M, Suematsu M, and Watanabe K. Aberrant utilization of nitric oxide and regulation of soluble guanylate cyclase in rat diabetic retinopathy. *Antioxidant and Redox Signaling* 2003; 5(4): 457-65
3. **Cameron-Schaefer S**, Kondo K, Ishige A, Tsuyama S, Uchida K, Hanawa T, Suematsu M, and Watanabe K. Maintaining the redox-balance intact: Gosha-jinki-gan but not insulin activates retinal soluble guanylate cyclase in diabetic rats.; *Ophthalmic Research* 2006; 38: 95-104
4. Matyakhina L, Bei TA, McWhinney SR, Pasini B, **Cameron S**, Gunawan B, Stergiopoulos SG, Boikos S, Muchow M, Dutra A, Pak E, Campo E, Cid MC, Gomez F, Gaillard RC, Assie G, Füzesi L, Baysal BE, Eng C, Carney JA, Stratakis CA. Genetics of Carney triad: recurrent losses at chromosome 1, but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. *Journal of Clinical Endocrinology and Metabolism* 2007; 92: 2938-2943
5. **Cameron S**, Haller F, Dudas J, Moriconi F, Gunawan B, Armbrust T, Langer C, Füzesi L, and Ramadori G. Immune cells in primary gastrointestinal stromal tumors. *European Journal of Gastroenterology and Hepatology* 2008; 20: 327-334
6. Haller F, Lökke C, Ruschhaupt M, **Cameron S**, Schulten H, Schwager S, Heydebreck A, Gunawan B, Langer C, Ramadori G, Sülzmann H, Poustka A, Korf U, Füzesi L. Loss of 9p leads to p16INK4A downregulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). *Journal of Pathology* 2008; 215:253-262
7. Homayounfar K, Gunawan B, **Cameron S**, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridisation. *Human Pathology* 2009; 40: 834-842
8. Armbrust T, Sobotta M, Haller F, Gunawan B, Füzesi L, Langer C, **Cameron S**, Ramadori G. Does Imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? – Single center experience. *European Journal of Gastroenterology and Hepatology* 2009; 21: 819-823.
9. Mansuroglu T, Baumhoer D, Dudas J, Haller F, **Cameron S**, Lorf T, Füzesi L, Ramadori G. Expression of stem cell factor (SCF) receptor c-kit in human non-tumoral and tumoral hepatic cells. *European Journal of Gastroenterology and Hepatology* 2009; 21: 1206-1211.
10. **Cameron S**, Hünerbein D, Mansuroglu T, Armbrust T, Scharf JG, Schwörer H, Füzesi L, Ramadori G. Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. *BMC Cancer* 2009;9(1):218
11. **Cameron S**, Savvoukidis T, Armbrust T, Haller F, Kitz J, Füzesi L, Ramadori G. Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and

- progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. *Medical Oncology* 2010; 27:213-218.
12. Haller F, Agaimy A, **Cameron S**, Beyer M, Gunawan B, Happel N, Langer C, Ramadori G, von Heydebreck A, Füzesi L. Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. *Histopathology* 2010; 56:305-318.
  13. Schaefer IM, Schüler P, Enders C, Scharf JG, **Cameron S**, Ramadori G, Füzesi L. High chromosomal instability in adenocarcinoma of the ileum arising in multifocal gastric heterotopia with gastritis cystica profunda.; *Medical Oncology*; 2011;28(4):1023-6.
  14. Haller F, Cortis J, Helfrich J, **Cameron S**, Schüler P, Schwager S, Gunawan B, Füzesi L, Agaimy A. Epithelioid/mixed phenotype in gastrointestinal stromal tumors with KIT mutation from the stomach is associated with accelerated passage of late phases of the cell cycle and shorter disease-free survival. *Modern Pathology* 2011; 24:248-255
  15. Blaschke M, **Cameron S**, Emami K, Blumberg J, Wegner U, Nischwitz M, Ramadori G. Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential. *International Journal of Clinical Pharmacology and Therapy* 2011; 49:83-85
  16. Streit F, Binder L, Hafke A, Brandhorst G, Bräulke F, Haase D, Armbrust T, **Cameron S**, Ramadori G, Oellerich M, Walson P. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. *Therapeutic Drug Monitoring* 2011; 33(5):632-43
  17. Schaefer IM, Enders C, Polten A, Haller F, Frölich AM, **Cameron S**, Schüler P, Schweiger P, Gunawan B, Beham A, Füzesi L. Common genomic aberrations in basaloid squamous cell carcinoma and carcinosarcoma of the esophagus detected by CGH and array CGH. *American Journal of Clinical Pathology* 2011; 135(4):579-586.
  18. Blaschke M, **Cameron S\***, Emami K, Blumberg J, Wegner U, Nischwitz M, Ramadori G, Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied. *Journal of Cancer Therapy* 2011; doi:10.4236/jct.2011; \*equal authors
  19. **Cameron S**, Schwartz A, Sultan S, Schaefer IM, Hermann R, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G. Radiation-induced damage in different segments of the rat intestine after external beam irradiation of the liver. *Experimental Journal of Pathology* – 2012; 92:243-258.
  20. Beham A, Schaefer IM, **Cameron S**, von Hammerstein K, Füzesi L, Ramadori G, Ghadimi M. Duodenal GIST: A single center experience; *International Journal of Colorectal disease* 2013; 28(4):581-90.
  21. Schaefer IM, **Cameron S**, Middel P, Homayounfar K, Schwörer H, Vieth M, Veits L. Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature. *BMC Cancer* 2012 Dec 4;12:570.
  22. Blaschke M, **Cameron S**, Goeschen C, Ramadori G. 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer. *Int J Clin Pharmacol Ther* 2013 Jan;51(1):56-8.
  23. Sultan S, **Cameron S**, Ahmad S, Martius G, Malik IA, Schultze FC, Rave-Fränk M, Christiansen H, Ramadori G. Serum lipocalin-2 is a potential biomarker of liver but not lung irradiation. *Liver Int* 2013 Mar;33(3):459-68.

24. Hupfeld T, Chapuy B, Schrader V, Beutler M, Veltkamp C, Koch R, **Cameron S**, Aung T, Haase D, Larosee P, Truemper L, Wulf GG. Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance. *Br J Haematol* 2013; 161:204-213.
25. Rave-Fraenk M, Malik I, Christiansen H, Naz N, Sultan S, Amanzada A, Blaschke M, **Cameron S**, Ahmad S, Ramadori G, Moriconi F. Rat model of fractionated (2Gy/day) 60 Gy irradiation of the liver: long-term effects. *Radiat Environment Biophys* 2013;52(3):321-38
26. Homayounfar K, Schwarz A, Enders C, **Cameron S**, Baumhoer D, Ramadori G, Lorf T, Gunawan B, Sander B. Etiologic influence on chromosomal aberrations in European hepatocellular carcinoma identified by CGH. *Pathol Res Pract.* 2013;209(6):380-7
27. Goralczyk AD, **Cameron S**, Amanzada A. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naive and --experienced patients. *BMC Gastroenterol.* 2013;13(1):148
28. Naz N, Ahmad S, **Cameron S**, Moriconi F, Rave-Fränk M, Christiansen H, Hess CF, Ramadori G, Malik IA. Differential Regulation of Ferritin Subunits and Iron Transport Proteins: An Effect of Targeted Hepatic X-Irradiation. *BioMed Research International* 2013, doi.org/10.1155/2013/353106
29. Schaefer IM, Delfs C, **Cameron S**, Gunawan B, Agaimy A, Ghadimi BM, Haller F. Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors. *Hum Pathol.* 2014;45(1):85-97
30. Amanzada A, Moriconi F, Mansuroglu T, **Cameron S**, Ramadori G, A Malik I. Induction of chemokines and cytokines before neutrophils and macrophage recruitment in different regions of rat liver after TAA administration. *Lab Invest.* 2014;94:235-247
31. Schaefer IM, Ströbel P, **Cameron S**, Beham A, Otto C, Schildhaus HU, Agaimy A. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behavior. *Histopathology* 2014;64:421-430
32. Tsaknakis B, Schaefer IM, Schwörer H, Sahlmann CO, Thoms KM, Blaschke M, Ramadori G, **Cameron S**. Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. *Med Oncol.* 2014;31(1):813.
33. Ahmad S, Sultan S, Naz N, Ahmad G, Alwahsh SM, **Cameron S**, Moriconi F, Ramadori G, Malik IA. Regulation of Iron Uptake in Primary Culture Rat Hepatocytes: The Role of Acute Phase Cytokines. *Shock.* 2014;41:337-345.
34. Khan S, **Cameron S**, Blaschke M, Moriconi F, Naz N, Amanzada A, Ramadori G, Malik IA. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: Role of cytokines. *World Journal of Gastroenterology* 2014, 20:2979-2994.
35. **Cameron S**, Gieselmann M, Blaschke M, Ramadori G, Füzesi L. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). *Int J Clin Exp Pathol* 2014; 7: 3563-3579
36. Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, **Cameron S**, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. *BMC Infect Dis* 2014;14:503.

37. Mechie NC, Röver C, **Cameron S**, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. *World J Hepatol* 2014;6(10):759-65.
38. Haller F, Zhang JD, Moskalev EA, Braun A, Otto C, Geddert H, Riazalhosseini Y, Ward A, Balwierz A, Schaefer IM, **Cameron S**, Ghadimi BM, Agaimy A, Fletcher JA, Hoheisel J, Hartmann A, Werner M, Wiemann S, Sahin O. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors (GISTs) reveals hypomethylation of SPP1 as an independent prognostic factor. *Int J Cancer* 2015; 136:1013-1023.
39. Martius G, **Cameron S**, Rave-Fränk M, Hess CF, Wolff HA, Malik IA. The Anti-TNF- $\alpha$  Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model; *Int J Mol Sci* 2015; 16:4682-4697.
40. Malik IA, Stange I, Martius G, **Cameron S**, Rave-Fränk M, Hess CF, Ellenrieder V, Wolff HA. Role of PECAM-1 in radiation-induced liver inflammation. *J Cell Mol Med* 2015; 19: 2441-2452.
41. Sultan S, Ahmad S, Rave-Fränk M, Malik IA, Hess CF, Christiansen H, **Cameron S**. Induction of Lipocalin 2 in a Rat Model of Lung Irradiation. *Int J Mol Sci* 2016; 17: E637. doi: 10.3390/ijms17050637.
42. Eriksson M, Reichardt P, Sundby Hall K, Schütte J, **Cameron S**, Hohenberger P, Bauer S, Leinonen M, Reichardt A, Rejmyr Davis M, Alvegard T, Joensuu H. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence? *Eur J Cancer* 2016; 59:128-133.
43. Merten L, Agaimy A, Moskalev EA, Giedl J, Kayser C, Geddert H, Schaefer IM, **Cameron S**, Werner M, Ströbel P, Hartmann A, Haller F. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors. *Am J Clin Pathol* 2016; 146:718-726. doi: 10.1093/ajcp/aqw193
44. Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, **Cameron S**, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2017 Mar 23. doi: 10.1001/jamaoncol.2016.5751.
45. He YJ, Kuchta K, Deng YM, **Cameron S**, Lin Y, Liu XY, Ye GR, Lv X, Kobayashi Y, Shu JC. Curcumin Promotes Apoptosis of Activated Hepatic Stellate Cells by Inhibiting Protein Expression of the MyD88 Pathway. *Planta Med* 2017; 83:1392-1396. doi:10.1055/s-0043-113044.
46. Bure I, Braun A, Kayser C, Geddert H, Schaefer IM, **Cameron S**, Ghadimi M, Ströbel P, Werner A, Hartmann A, Wiemann S, Agaimy A, Haller F, Moskalev E. The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a site-dependent manner in gastrointestinal stromal tumours (GISTs). *Int J Can* 2017; 141(11):2296-2304. doi: 10.1002/ijc.30905.
47. Ahmad S, **Cameron S**, Naz N, Moriconi F. Mediators of hypoxia in a rat model of sterile induced acute liver injury. *Int J Clin Exp Pathol* 2017; 10(12):11471-11479.
48. Flemming J, **Cameron S**. Small bowel capsule endoscopy. Indications, results, and clinical benefit in a University environment. *Medicine* 2018; 97:e0148.

49. **Cameron S**, Kuchta K, Reissenweber-Hewel H. Kampo-Medizin in der gastrointestinalen Onkologie. *Zkm* 2018; 3:50-57.
50. **Cameron S**. Gastrointestinale Stromatumoren. Bedeutung der Molekularen Diagnostik für Prognose und Therapie. *Der Gastroenterologe* 2018; epub 5-2018/16064340.
51. Sander B, **Cameron S**, Gunawan B, Füzesi L. Optimal thresholds of risk parameters for gastrointestinal stromal tumors. *Eur J Surg Oncol* 2019; doi: 10.1016/j.ejso.2019.08.009.
52. Mechie NC, Mavropoulou E, Ellenrieder V, Kunsch S, **Cameron S**, Amanzada A. Distinct association of serum vitamin D concentration with disease activity and trough levels of infliximab and adalimumab in inflammatory bowel disease treatment. *Digestion* 2019-3-9. doi.org/10.1159/000502515.
53. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schuette J, **Cameron S**, Hohenberger P, Jost P, Al-Batran S-E, Lindner LH, Bauer S, Wardelmann E, Nilsson BE, Kallio RS, Jaakkola P, Junnila J, Alvegård T, Reichardt P. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up. *Journal of Clinical Oncology* 2020; 38:15\_suppl. 11503-11503; doi: 10.1200/JCO.2020.38.15.
54. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, **Cameron S**, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. *JAMA Oncol.* 2020;6(8):1241-1246. doi:10.1001/jamaoncol.2020.2091
55. Kuchta K, **Cameron S**. Tradition to Pathogenesis: A novel hypothesis for Elucidating the pathogenesis of Diseases Based on the Traditional Use of Medicinal Plants. *Front. Pharmacol.* 2021; 12:705077. doi: 10.3389/fphar.2021.705077
56. Ammer-Herrmenau C, Asendorf T, Beyer G, Buchholz SM, **Cameron S**, Damm M, Frost F, Henker R, Jaster R, Phillip V, Placzek M, Ratei C, Sirtl S, van den Berg T, Weingarten MJ, Woitalla J, Mayerle J, Ellenrieder V, Neesse A. Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis—a prospective multicentre translational study. *BMC Gastroenterol* 2021; 21:304. doi.org/10.1186/s12876-021-01885-4
57. Golas MM, Gunawan B, Cakir M, **Cameron S**, Enders C, Liersch T, Füzesi L, Sander B. Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. *Colorectal Dis.* 2022; 24: 157–176. <https://doi.org/10.1111/codi.15946>
58. Krebs N, Klein L, Wegwitz F, Espinet E, Maurer, Tu M, Penz F, Küffer S, Xu X, Bohnenberger H, **Cameron S**, Brunner M, Neesse A, Kishore U, Hessmann E, Trumpp A, Ströbel P, Brekken RA, Ellenrieder V, Singh SK. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. *JCI Insight.* 2022;7(16):e154475. doi.org/10.1172/jci.insight.154475.
59. Joensuu H, Wardelmann E, Eriksson M, Reichardt A, Sundby Hall K, Schütte J, **Cameron S**, Hohenberger P, Sihto H, Jost PJ, Lindner LH, Bauer S, Nilsson B, Kallio R, Pesonen T, Reichardt P. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial. *Cancer Res* 2023; doi: 10.1158/1078-0432.CCR-22-3980

60. Reißerweber-Hewel H, Pehl C, **Cameron S**, Thomsen J, Röschmann-Doose K. Treatment of dyspeptic symptoms with Yamato®Gast. A non-interventional study of a registered traditional herbal *Rikkunshito* extract product from Japanese Kampo Medicine in routine practice in Germany. *Z Gastroenterol* 2023, doi: 10.1055/a-2164-4534
61. Ammer-Herrmenau C, Antweiler KL, Asendorf T, Beyer G, Buchholz SM, **Cameron S**, Capurso G, Damm M, Frost F, Gomes A, Henker R, Hoffmeister A, Meinhardt C, Nawacki L, Nunes V, Panyko A, Pardo C, Phillip V, Pukitis A, Rasch S, Riekstina D, Rinjia E, Ruiz Rebollo ML, Sirtl S, Weingarten M, Vasile S, Woitalla J, Ellenrieder V, Neesse A. Pancreatitis – Microbiome As Predictor of Severity (P-MAPS) – A European multicentric prospective cohort study. *GUT* 2024; 73:485–495. doi:10.1136/gutjnl-2023-330987
62. Joensuu H, Reichardt A, Eriksson M, Hohenberger P, Boye K, **Cameron S**, Lindner L-H, Jost P-J, Bauer S, Schütte J, Lindskog S, Kallio R, Jaakkola P-M, Goplen D, Wardelmann E, Reichardt P. Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial. 2024. *BJC*. *Accepted*.
63. Zedler P, Faßhauer M, **Cameron S**. Pankreaskarzinom – Bedeutung der prädiagnostischen Bildgebung. 2024. *Bayerisches Ärzteblatt*. *Accepted*.

### Übersichtsartikel

1. Reissenweber H, **Schäfer S**. Japanische Phytotherapie (Kampo) – Klinische Relevanz und Qualitätssicherung in der Modernen Medizin, Symposium Phytopharmaka VI, June 2000; *Proceedings of the German Society for Clinical Pharmacology and Therapy* 2001
2. **Schäfer S**. Kampo – Japanische Phytotherapie; *Symposium Medical – Naturheilkunde*; BMV Berliner Medizinische Verlagsanstalt GmbH 2001; 11. Jahrgang: 38-39
3. **Cameron S**, Ramadori G. Familiäre Gastrointestinale Stromatumoren.; *Tumor Diagnostik & Therapie*, Thieme Verlag Stuttgart 2004; 25: 189-191
4. **Cameron S**, Ramadori G. Gastrointestinal stromal tumors: diagnostics, therapy and beyond? *Minerva Gastroenterol Dietol*. 2009; 55(4):409-423.
5. Ramadori G, **Cameron S**. Effects of systemic chemotherapy on the liver. *Annals of Hepatology* 2010; 9:133-143
6. **Cameron S**, Ramadori G. Beitrag der Gastroenterologie zur Therapie – 15 Jahre Erfahrung: aus der Vielfalt Hoffnung schöpfen. *Glandula-NET Jubiläumsausgabe* 2010
7. **Cameron S**. Lebererkrankungen im Alter, weniger aggressiv behandeln? *MedReview* 14;2011: 11-13
8. Beham AW, Schaefer IM, Schüler P, **Cameron S**, Ghadimi BM. Gastrointestinal stromal tumors. *Int J Colorectal Dis*. 2012;27(6):689-700
9. Agaimy A, Bauer S, Beham A, Bertolini J, Haller F, Koschny R, Maier J, Montemurro M, Perez D, Schaefer IM, Schildhaus HU, Wurst C, **Cameron S**. Gastrointestinal Stromal Tumours (GIST) - development in pathology, surgery and medical therapy. *Z Gastroenterol*. 2015; 53(3):235-43.
10. **Cameron S**. Gastrointestinaler Stromatumor (GIST). *Gastroenterologie up2date* 11;2015 doi.org/10.1055/s-0034-1392312.

11. **Cameron S**, Beham A, Schildhaus H-U. Current standard and future perspectives in the treatment of gastrointestinal stromal tumors (GIST). *Digestion*; 2017; DOI: 10.1159/000455835.
12. Reichardt P, Reichardt A, **Cameron S**. Gastrointestinale Stromatumoren (GIST). *Der Gastroenterologe*; 2017; DOI 10.1007/s11377-016-0131-3.
13. **Cameron S**. Gastrointestinale Stromatumore. Bedeutung der Molekularen Diagnostik für Prognose und Therapie. *Wien klin Mag*; 2018; DOI 10.1007/s00740-018-0257-7
14. Kuchta K, **Cameron S**. Phytotherapy for Cachexia: Where do we stand? *Front. Pharmacol.* 2020; 11:917. doi: 10.3389/fphar.2020.00917
15. Kuchta K, **Cameron S**, Lee M, Cai SQ, Shoyama Y. Which East Asian herbal medicines can decrease viral infections. *Phytochem Rev* 2021; doi.org/10.1007/s11101-021-09756-2
16. Motoo Y, **Cameron S**. Kampo medicines for supportive care of patients with cancer: A brief review. *Int Med Res* 2022; 11 (2). doi.org/10.1016/j.imr.2022.100839
17. Motoo Y, **Cameron S**. Significance of Kampo medicine for cancer supportive care: Overview. *Traditional & Kampo Medicine* 2023; <https://doi.org/10.1002/tkm2.1363>
18. Brendler T, **Cameron S**, Kuchta K. Uzara (*Xysmalobium undulatum*) – An underutilized anti-diarrhoeic and spasmolytic herbal remedy. *J Ethnopharmacol* 2023; doi.org/10.1016/j.jep.2023.116999

### **Fallberichte und Editorials**

1. Ramadori G, **Cameron S**, Tschechne B. Long-Lasting tumor response in patients with panitumumab monotherapy for chemorefractory metastatic colorectal carcinoma – A report of two cases. *Case Reports in Oncology* 2010; 3:154-159
2. Amanzada A, Töppler GJ, **Cameron S**, Schwörer H, Ramadori G. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. *Case Reports in Oncology* 2010;3(3):463-70
3. **Cameron S**, Schaefer IM, Schworer H, Ramadori G. Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor. *Case Reports in Oncology* 2011; 4(3):505-511
4. **Cameron S**. Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib – a comment and reflection on the PERSIST-5 study. *Transl Gastroenterol Hepatol* 2018;3:16.doi:21037/tgh.2018.03.01
5. Kuchta K, **Cameron S**. Kampo Medicine in a Modern Context: Ethnopharmacological Perspectives. *Front. Pharmacol.* 2022; 13:971254. doi: 10.3389/fphar.2022.971254

## Kommentare und Letters

1. **Schäfer S**, Ramadori G. Vom Adenom zum Karzinom – Wie festgefahren sind die Wege der Mutationen? *Zeitschrift für Gastroenterologie* 2003; 41: 201-03.
2. **Cameron S**, Ramadori G, Füzesi L, Sattler B, Gunawan B, Müller D, Ringe B, Lorf T. Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. *Transplantation* 2005; 80: 283-284.
3. **Cameron S**, Reissenweber H, Watanabe K. Asian medicine: Japan's paradigm; *Nature*. 2012 Feb 1;482(7383):35. doi: 10.1038/482035a.
4. **Cameron S**. Commentary on: Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). *International J Clin Oncol*. 2020;25:1123-1129; *Complement Med Res* 2021;28:9–14 doi: 10.1159/000514012
5. Motoo Y, Nishiuchi T, Uezono Y, **Cameron S**. Significance of Kampo medicine in cancer supportive care“1st International Symposium on Kampo Medicine. *Traditional & Kampo Medicine* 2022; doi.org/10.1002/tkm2.1319
6. **Cameron S**. Johann Andreas Eisenbarth (1663–1727) und Todo Yoshimasu (1702–1772), Ein Vergleich der Medizin des Barocks und der japanischen Edo-Zeit. *Zeitschrift für Phytotherapie* 2023; 44(06): 268-273.

## Buchartikel

- Möhler M, **Cameron S**, Menges M. Magentumore / GIST. Kapitel 3.4, in: Rationelle Diagnostik und Therapie in der Inneren Medizin, Leitlinien-basierte Empfehlungen für die Praxis; Elsevier, Urban&Fischer, 2012 ISBN 978.3-437-22827-8. Hrgs. Busse O, Fleig WE, Mayet WJ, Mertens PR, Meyer J, Müller OA, et al.
- Menges M, Möhler M, **Cameron S**. Magentumore / GIST. Kapitel 3.4, in: Rationelle Diagnostik und Therapie in der Inneren Medizin, Leitlinien-basierte Empfehlungen für die Praxis; Elsevier, Urban&Fischer, 2021. Hrgs. Busse O, Fleig WE, Mayet WJ, Mertens PR, Meyer J, Müller OA, et al.
- Rausch H, Schröder S, Friedemann T, **Cameron S**, Kuchta K, Konrad M. History and Present of European Traditional Herbal Medicine (Phytotherapy). In: Shen Y (Editor): History, Present and Prospect of World Traditional Medicine (in 2 Volumes). 2023, World Scientific Publishing Co Pte Ltd. ISBN 978-981-12-8710-7.

## Eingereicht

- Napp J, Siebel P, Rausch H, Kuchta K, Efferth T, Alves F, Ellenrieder V, **Cameron S**. Prolonged survival by combination treatment of a standardized herbal extract from Japanese Kampo-Medicine (Juzentaihoto) and Gemcitabine in an orthotopic transplantation pancreatic cancer model. *Frontiers in Oncology* Eingereicht 05/2024.
- Zedler P, Büntzel J, Kuchta K, Yamaoka D, Sato N, Watanabe K, and **Cameron S**. Clinical Signs and Symptoms: Kampo Pattern Diagnosis in modern Gastrointestinal Disease. *Frontiers in Ethnopharmacology* Eingereicht 05/2024.